Revolution Medicines' KRAS Inhibitor RMC-6292 Shows Strong Clinical Data at AACR 2026

Revolution Medicines presented compelling new clinical data at AACR 2026 for its investigational KRAS G12C inhibitor, RMC-6292. The data, gathered from ongoing trials, highlighted promising anti-tumor activity and a favorable safety profile in patients with various solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer. RMC-6292, a next-generation inhibitor, aims to overcome limitations of earlier therapies by offering enhanced potency and selectivity. The presented results showed objective response rates and durable disease control, suggesting a significant potential for patients with limited treatment options. While further studies are needed to fully elucidate its long-term efficacy and optimal use, the findings position RMC-6292 as a potentially important new weapon in the fight against KRAS-mutated cancers. The company is advancing RMC-6292 in combination strategies, signaling a forward-looking approach to expand its therapeutic reach.